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Abstract 
Scleroderma is a female-prevalent autoimmune disease of unclear etiology. Two 
fundamental gender differences, skewed X-chromosome inactivation (XCI) and 
pregnancy-related microchimerism have been implicated in scleroderma. We 
investigated the XCI patterns of female scleroderma patients and the parental origin 
of the inactive X chromosome in those patients having skewed XCI patterns (>80%). 
In addition, we investigated whether a correlation exists between XCI patterns and 
microchimerism in a well-characterized cohort. 195 female scleroderma patients and 
160 female controls were analyzed for the androgen receptor locus to assess XCI 
patterns in the DNA extracted from peripheral blood cells. Skewed XCI was observed 
in 67 (44.9%) of 149 informative patients and in 10 of 124 healthy controls (8.0%) 
[odds ratio (OR) = 9.3 (95% confidence interval (CI) 4.3-20.6, P<0.0001)]. Extremely 
skewed XCI (>90%) was present in 44 of 149 patients (29.5%) but only in 3 of 124 
controls (2.4%)  (OR=16.9; 95% CI 4.8-70.4, P<0.0001).  Parental origin of the 
inactive X chromosome was investigated for 10 patients for whom maternal DNA was 
informative, and the inactive X chromosome was of maternal origin in 8 patients and 
of paternal origin in 2 patients. Skewed XCI mosaicism could be considered as an 
important risk factor in scleroderma.  
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Introduction 
Scleroderma (systemic sclerosis, SSc) is an autoimmune disease characterized by 
fibrosis, and alterations in the microvasculature. (1) Scleroderma is 3-10 times more 
prevalent in women than in men. (2) Most autoimmune diseases are more prevalent 
in females than in males, (3) and fundamental differences between male and female 
biology, such as hormone status, (4) pregnancy, (5) and X-chromosome inactivation 
(6,7) have been proposed as the underlying pathophysiological mechanisms leading 
to the female prevalence of autoimmune diseases. Indeed, both pregnancy-related 
microchimerism, (8,9,10,11) and skewed (i.e., not the expected 50:50 balance) X-
inactivation mosaicism (12) have been shown to be associated with scleroderma.  
 
This study was performed to investigate the X-inactivation patterns of female 
scleroderma patients along with the parental origin of the inactive X chromosome in 
those patients with extremely skewed X-inactivation. In addition, the correlation 
between skewed X-inactivation and both maternal and fetal microchimerism was 
examined in a well-characterized cohort of scleroderma patients.  
 
Patients and Method 
DNA samples were obtained from 195 scleroderma patients and 160 control women.  
Clinical characteristics of the patients and controls have been published elsewhere. 
(12,13) The ethics review boards at the participating institutions approved the study 
protocol. Informed consent was obtained from all subjects. The X-chromosome 
inactivation status of the patients and controls was determined by genotyping a highly 
polymorphic CAG repeat in the first intron of the androgen receptor as previously 
described. (12,14) Depending on the definition and quantitative accuracy of the 
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measurement method, a few percent to nearly one fifth of apparently healthy women 
display skewed (i.e., non-random) patterns of X-inactivation. Whereas, ratios in the 
range of 50-79 percent is usually regarded as normal variation, deviation from this 
range in 80-89 percent of cells is defined as skewed, and above 90 percent of cells 
as extremely skewed X-inactivation. (15,16,17) Fisher’s Exact test was used for 
statistical analyses.  
 
Results  
X-inactivation ratios 
Our data show that skewed X-chromosome inactivation (>80%) was associated with 
disease. X-chromosome inactivation status was informative in 94 of the 125 
scleroderma patients (75%) and in 124 of the 160 controls (78%). Only the 
individuals whose alleles resolved adequately were included in the subsequent 
densitometric analysis, thus some of the heterozygous individuals were considered 
as uninformative. Skewing in the range of 80-89% was observed in 15 of the 94 
patients (16.0%) but in only 7 of the 124 controls (5.6%; P<0.0001; Table 1).  
Extremely skewed X-inactivation (>90%) was observed in 17 of the 94 patients 
(18.1%) but in only 3 of the 124 controls (2.4%; P<0.0001). When the data from the 
present and the previously published (12) studies were combined (Table 1), of the 
total of 195 patients, 149 were informative for the androgen receptor polymorphism. 
Skewed X-inactivation was observed in 67 of 149 patients (44.9%) but in only 10 of 
124 healthy controls (8.0%). Expressed as a risk factor for scleroderma, the odds 
ratio (OR) was 9.3 (95% confidence interval (CI) 4.3-20.6; P<.0001). Numerous 
studies conducted in different control populations indicate that extremely skewed X-
inactivation is a rare event not exceeding 3-5 percent. (15,16,17) For the current 
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study, extremely skewed X-inactivation was present in 44 of 149 patients (29.5%) but 
in only 3 controls (2.4%) and the OR was 16.9 (95% CI 4.8-70.4, P<0.0001).   
 
Parental origin of the inactive X chromosome 
19 patients with skewed X-inactivation for whom maternal DNA was available were 
further analyzed to determine the parental origin of the inactive X chromosome. For 
this analysis, DNA samples from mothers of patients were analyzed for the androgen 
receptor gene polymorphism, and informative results were obtained for ten patient-
mother pairs. For the remaining 9 pairs, both the mother and the daughter were 
heterozygous for the androgen receptor polymorphism, thus providing no difference 
in allele sizes. Therefore, it is not possible to determine the parental origin of the 
alleles in the absence of information regarding the paternal genotype. The inactive X 
chromosome was of maternal origin in 8 patients and of paternal origin in 2 patients. 
In 3 mothers of patients studied, X-inactivation pattern was also skewed (Table 2).  
Interestingly, the same allele was skewed in both the mothers and the patients, and 
one mother had been diagnosed with an autoimmune condition, namely temporal 
arteritis.    
 
Evaluation of skewed X-inactivation for correlation with microchimerism 
Maternal and fetal microchimerism was investigated as described previously. (18) We 
examined X-inactivation ratios for correlation with microchimerism in a limited number 
of patients for whom microchimerism data was also available. We observed that 
among patients with more than 80 percent skewing, 7 of 12 (58.3%) tested positive 
for maternal microchimerism and 8 of 14 (57.1%) for fetal microchimerism (Table 3).  
In patients with random patterns of X-inactivation, 10 of 15 (66.7%) were positive for 
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maternal microchimerism, and 14 of 25 patients were positive for fetal 
microchimerism (56%). Neither maternal (P=0.7) nor fetal microchimerism (P=1.0) 
correlated with skewed X-inactivation. 
 
Discussion 
Autoimmune disorders affect more than 5% of the population, and a high female 
prevalence is characteristic of most autoimmune diseases including scleroderma, 
autoimmune thyroid diseases, systemic lupus erythematosus, and Sjögren’s 
syndrome. (3) Pregnancy related microchimerism, (10) and skewed X-inactivation 
(12) have been proposed as potential contributors to the pathophysiology of 
scleroderma. In this study we observed skewed X-inactivation patterns in a significant 
proportion (34%) of females with scleroderma. Of these females, approximately 18% 
displayed extreme skewing (>90:10). This result is consistent with our previous study, 
(12) and indicates that skewed X-inactivation could be a common finding in different 
population groups.   
 
We do not know the cause of skewed X inactivation in scleroderma, and probable 
mechanisms have been discussed in the accompanying manuscript. (19) Amongst 
them, X-linked lethal mutations, which would be compatible with life in females 
because of X-inactivation mosaicism, is an appealing causative mechanism. If the 
cause of skewing is indeed X-linked mutations, these should be inherited from the 
maternal lineage unless they occur de novo during gametogenesis. We therefore 
analyzed the parental origin of the inactive X chromosome in 19 patient-mother pairs, 
and of the 10 pairs with informative genotyping results, inactive X was found to be of 
maternal origin in eight pairs. This result is on the border of statistical significance 
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(P=0.055). Assuming this result holds, we will be left with an interesting puzzle. Why 
are maternally inherited X chromosomes more likely to be inactivated in highly 
skewed patients? One possibility is that some X chromosomes confer a selective 
disadvantage to both the organism itself and the peripheral cells within the organism. 
This precise situation has been documented in X-linked immunodeficiency, where 
heterozygous (female) carriers have high X-inactivation skew (because of natural 
selection within the organism), while affected males have a survival disadvantage. 
(20) When an X-encoded genotype is selectively disadvantageous to cells, skew is 
an outcome. When an X-encoded genotype is selectively disadvantageous to an 
organism, preferential maternal inheritance is an outcome. Together, this leads us to 
the hypothesis that some highly skewed patients have an X chromosome that would 
confer a selective disadvantage on homozygotic women and on males. 
 
Because scleroderma is the first disease in which pregnancy related microchimerism 
has been documented, we investigated a subset of patients for whom 
microchimerism data was also available for correlation of skewed X-inactivation with 
microchimerism. Neither maternal nor fetal microchimerism were found to be 
correlated with skewed X-inactivation. In conclusion, the two types of female 
mosaicism—skewed X-inactivation and maternal/fetal microchimerism—appear to be 
independent risk factors in scleroderma. One possible explanation for these data is 
that mosaicism itself is an underlying cause of scleroderma and, by extension, 
female-prevalent autoimmune disease in general. 
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 Table 1. Proportions of scleroderma patients and controls with skewed X-inactivation. 
 
 No. (%) observed with skewing 
 Present 
study 
Previous 
study11 
Combined Control 
Degree of 
skewing (%) 
(n=94) (n=55) (n=149) (n=124) 
+90 17 (18.1%) 27 (49.1%) 44 (29.5%) 3 (2.4%) 
80-89 15 (16.0%)   8 (14.5%) 23 (15.4%) 7 (5.6%) 
70-79 15 (16.0%) 0 (0.0%) 15 (10.1%) 22 (17.7%) 
60-69 24 (25.5%) 5 (9.1%) 29 (19.5%) 29 (23.4%) 
50-59 23 (24.5%) 15 (27.3%) 38 (25.5%) 63 (50.8%) 
For comparison by χ2, P<0.0001(both >80% skewing and >90% skewing) 
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Table 2. Parental origin of the inactive X chromosome in scleroderma 
patients with skewed X-inactivation. 
 
Sample Degree of 
skewing 
Parental origin of the 
inactive X chromosome 
Patient 1  95 Maternal 
Mother 1  95  
   
Patient 2  95 Maternal 
Mother 2 95  
   
Patient 3 86 Maternal 
Mother 3 88  
   
Patient 4 100 Maternal 
Mother 4 Not informative  
   
Patient 5 90 Maternal 
Mother 5 Not informative  
   
Patient 6 90 Maternal 
Mother 6 Not informative  
   
Patient 7 85 Maternal 
Mother 7 67  
   
Patient 8 85 Maternal 
Mother 8 58  
   
Patient 9 85 Paternal 
Mother 9 70  
   
Patient 10 80 Paternal 
Mother 10 70  
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Table 3. Proportion of maternal (MMc) and fetal (FMc) microchimerism in 
scleroderma patients. 
 
    MMc                                                          FMc 
Skewed 
(>80 %) 
 
12 tested 58.3% 
positive for 
MMc 
Skewed 
(>80 %) 
14 tested 57.1% 
positive for 
FMc 
 7 positive   8 positive  
 5 negative   6 negative  
Random 
(<80 %) 
15 tested 66.7% 
positive for 
MMc 
Random 
(<80 %) 
25 tested 56.0% 
positive for 
FMc 
 10 positive   14 positive  
 5 negative   11 negative   
 
